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Gemcitabine-mediated tumour regression and
p53-dependent gene expression: implications for
colon and pancreatic cancer therapy
R Hill1,2,6, M Rabb2, PA Madureira1, D Clements3, SA Gujar2, DM Waisman4, CA Giacomantonio3,4,5 and PW K Lee*,1,2,3
Gemcitabine is a chemotherapeutic that is widely used for the treatment of a variety of haematological malignancies and has
become the standard chemotherapy for the treatment of advanced pancreatic cancer. Combinational gemcitabine regimes
(e.g.with doxorubicin) are being tested in clinical trials to treat a variety of cancers, including colon cancer. The limited success
of these trials has prompted us to pursue a better understanding of gemcitabine’s mechanism of cell killing, which could
dramatically improve the therapeutic potential of this agent. For comparison, we included gamma irradiation that triggers robust
cell cycle arrest and Cr(VI), which is a highly toxic chemical that induces a robust p53-dependent apoptotic response.
Gemcitabine induced a potent p53-dependent apoptosis that correlated with the accumulation of pro-apoptotic proteins such as
PUMA and Bax. This is accompanied by a drastic reduction in p2l and 14-3-3r protein levels, thereby significantly sensitizing the
cells to apoptosis. In vitro and in vivo studies demonstrated that gemcitabine required PUMA transcription to instigate an
apoptotic programme. This was in contrast to Cr(VI)-induced apoptosis that required Bax and was independent of transcription.
An examination of clinical colon and pancreatic cancer tissues shows higher p53, p21, 14-3-3r and Bax expression compared
with matched normal tissues, yet there is a near absence of PUMA protein. This may explain why gemcitabine shows only limited
efficacy in the treatment of these cancers. Our results raise the possibility that targeting the Bax-dependent cell death pathway,
rather than the PUMA pathway, could result in significantly improved patient outcome and prognosis for these cancers.
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The tumour-suppressor p53 regulates cell cycle arrest,
apoptosis or senescence1–4 and is one of the most frequently
mutated proteins in cancer.5,6 Cellular stress mediates p53
stabilization directing cell cycle arrest (controlled by p21 and
14-3-3s) or apoptosis (requiring PUMA, Bax, Noxa or BID).5,7
The p53-dependent expression of PUMA has been shown
as a key determinant of transcription-dependent apoptosis as
the phenotype of [PUMA / ] HCT116 cells are strikingly
similar to that of [p53 / ] HCT116 cells.8,9 There is also a
transcription-independent p53 response to cellular stress,10–12
whereas p53-dependent apoptosis can be readily observed in
the absence of PUMA correlating with the cytosolic accumula-
tion of p53 and activation of Bax.13,14 p53 can directly interact
with Bax, mediating the latter’s oligomerization inducing the
permeabilization of mitochondria. Although Bax is a clear
component of p53-mediated transcription-independent cell
death, Bax transcription is regulated by p53, highlighting the
overlap between these mechanisms to induce apoptosis.15
Most anti-cancer drugs in use today are selected on
their ability to induce apoptotic cell death. Gemcitabine
(a deoxycytidine analogue) has become the standard
chemotherapeutic for the treatment of advanced pancreatic
cancer and is currently in phase II clinical trials to treat colon
cancer.16–18 There are also apoptosis-inducing chemicals
including chromium (Cr(VI))19 that is highly toxic introducing
chromium–DNA adducts and DNA breaks.20–22
We compare gemcitabine with the Cr(VI) evaluating their
mechanism of action regarding apoptosis induction. We
demonstrate that gemcitabine-induced apoptosis is mediated
in a p53 transcription- and PUMA-dependent manner. Cr(VI)
exposure mediates a potent p53-dependent apoptotic effect
that is transcription-independent but required the protein
Bax. For both, there is the requirement for the loss of p21 and/
or 14-3-3s prior to the induction of apoptosis, whereas the loss
of either prior to treatment significantly increased sensitivity to
each compound. Although these compounds were effective in
reducing tumour burden of [p53þ /þ ] HCT116 tumours in
mice, they showed differential effects on [PUMA / ] and
[Bax / ] HCT116 tumours that mirrored those observed
in vitro. Primary colon or pancreatic cancer patient sample
analysis revealed significant p53 accumulation and activation
within tumour tissues yet the striking absence of the PUMA
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protein (in contrast to Bax). As gemcitabine is currently being
used to treat pancreatic and colon cancer with limited efficacy,
our results raise the possibility that targeting the Bax-
dependent apoptotic pathway could offer significantly
improved patient outcome.
Results
Cell line exposure to gemcitabine or chromium induces
the accumulation of p53 and mediates a potent apoptotic
response. To establish the cellular conditions that induced
significant cell death following exposure to each agent
(gemcitabine or Cr(VI)), the EC50 values for our cell lines
were determined using the MTS assay. Each compound
induced significant cell death in the p53-containing cell lines
but not p53-deficient cells lines at 72 h post treatment
(Figure 1a). There was no significant change in cell line
viability following g-IR exposure (10 Gy) (data not shown).
Western blot analysis of [p53þ /þ ] HCT116 and U2OS cells
showed that induction of cell death by these chemicals was
accompanied by pronounced accumulation of p53 as well as
cleaved caspase-2, caspase-3 and caspase-9 (Figure 1b).
We did not detect p53 accumulation nor caspase cleavage in
the [p53 / ] HCT116 or Saos-2 cell lines. In agreement with
the immunoblot data, annexin-V staining of cells 48 h
following exposure to gemcitabine or Cr(VI), but not g-IR,
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Figure 1 p53 is required for gemcitabine- and Cr(VI)-mediated cell death. (a) At 72 h post chemical exposure, MTS assays were conducted for each cell line shown. Stable
knockdown cell lines were generated using our retrovirus expression system (pSUPER-Retro) and selected and cultured in puromycin (2 mg/ml) for the duration of our studies.
Results are mean±S.D.; ***Po0.0001, *Po0.05. Each assay was conducted in triplicate and each set of experiments was repeated three times. (b) Cell lines were treated
(10mM Gemcitabine, 30mM Cr(VI) or 10 Gy g-IR) for 48 h and lysates were prepared and subjected to SDS-PAGE. Immunoblotting was carried out using caspase-3, caspase-
9, caspase-2, p53 and b-actin antibodies. (c) At 48 h post DNA damage, annexin-V staining was carried out following the manufacturer’s guidelines. The percentage of positive
cells was determined by FACS analysis (Becton Dickinson, Franklin Lakes, NJ, USA). Results are mean±S.D. n¼ 3
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showed increased annexin-V staining in cells containing p53
(Figure 1c).
Each DNA damage agent induces the accumulation of
p53-regulated pro-apoptotic proteins. We investigated if
there was any difference between these agents in inducing
the accumulation of key BH3-family proteins. Cell lines were
exposed to gemcitabine, Cr(VI) or g-IR for 48 h. Under each
damage condition, we observe accumulation of PUMA and
Bax proteins in p53-containing cell lines (Figure 2a).
Consistent with the induction of apoptosis there was
significant BID accumulation and cleavage, particularly in
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Figure 2 BH3-family transcription and translation is conserved regardless of damage modality. (a) Indicated cell lines were exposed to gemcitabine (10mM), Cr(VI)
(30mM) or g-IR (10 Gy) for 48 h. Immunoblotting was carried out for Bcl-2, Bcl-xL, Bid, Bax, PUMA, p53 and b-actin. (b) Cells were treated as indicated and RNA was extracted
using Trizol (Invitrogen). cDNA was generated (superscript II, Invitrogen) and qRT-PCR (Sybr Green, Stratagene) was carried out for Bcl-2, Bcl-xL, Bid, Bax, PUMA and
GAPDH. Expression was normalized to GAPDH and gene expression (fold change) was calculated using the 2DDCT formula. Each assay was conducted in quadruplicate,
N¼ 3
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cells exposed to gemcitabine or Cr(VI). A reduction in the
level of the anti-apoptotic proteins Bcl-2 and Bcl-xL was also
evident in these treated cells. Overall, gemcitabine and
Cr(VI) treatment greatly altered the ratios of pro-apoptotic
proteins (Bax/PUMA/cleaved BID) to anti-apoptotic proteins
(Bcl-2/Bcl-xL) in p53-containg cells.
To determine if the protein level correlated with gene
transcription, we conducted a quantitative real time PCR
screen (Figure 2b). There was the induction ofPUMA and Bax
in all p53-containing cells exposed to any of the treatments.
We did not observe a significant change in Bid transcription
suggesting that BID stabilization and cleavage was important
for its apoptotic function after treatment. In cells exposed to
Cr(VI) or gemcitabine, the Bcl-2 and Bcl-xL expression levels
were either reduced (Bcl-2) or remained unchanged (Bcl-xL).
In contrast (and in agreement with the immunoblot data), for
both the [p53 / ] HCT116 and the Saos-2 cell lines, there
was significantly reduced expression of PUMA and Bax, but
no change in Bcl-2 or Bcl-xL expression. It is interesting that
g-IR that promotes cell growth arrest (but not apoptosis)
generated similar BH3-family gene expression profiles.
Reduction of p21 and 14-3-3r correlates with the
induction of apoptosis following DNA damage and the
loss of both synergistically increases this sensitivity.
Following our BH3-family expression screen, we examined
both the protein levels and the transcript levels of the cyclin-
dependent inhibitor 1A (p21) and the cell cycle arrest protein
14-3-3s, (both key p53-regulated proteins) and protect cells
from p53-dependent apoptosis.23–28 Whereas exposure to
g-IR resulted in elevated p21 and 14-3-3s expression at
both the transcript and protein levels (Figures 3a and b),
gemcitabine and Cr(VI) displayed significant suppression of
expression and a corresponding lowered protein level of
these two genes. Although the loss of p21 mRNA expression
following chromium exposure has previously been
reported,29,30 the observation that the chemotherapeutic
drug gemcitabine showed a similar repression of p21
expression was revealing, particularly when one considers
that the expression of the 14-3-3s protein, which comple-
ments p21 in blocking cell progression at G2, was also
repressed.
We questioned if the knockout or knockdown of either p21
or 14-3-3s would enhance the sensitivity of p53-containing
cells to these drugs. Our data (Figure 3c) clearly showed that
knockout or the knockdown of p21 or 14-3-3s significantly
increased the sensitivity of wild-type p53-containing cells
to gemcitabine and Cr(VI) and the double knockout
[p21 / ][14-3-3s / ] HCT116 cells show a synergistically
increased sensitivity to gemcitabine and Cr(VI) compared with
either single knockout. Exposure of these knockdown or
knockout cell lines to g-IR failed to significantly increase cell
death even at the highest g-IR doses investigated (data not
shown).
Gemcitabine requires transcription to trigger apoptosis
in contrast to Cr(VI). Gemcitabine and Cr(VI) both induced
p53-dependent cell death (Figure 1) and each significantly
increased the transcription of the pro-apoptotic genes Bax
and PUMA (Figure 2), we questioned if cell line sensitivity
was affected if transcription was inhibited. Each cell line was
pretreated with actinomycin D inhibiting transcription.31–33
We observed significantly increased cell line resistance to
gemcitabine, generating EC50 values that were similar to
those from cell lines that lack p53 (Figure 4a). Cr(VI)-induced
cell death was transcription-independent.
We examined the protein expression profile of p53 and
p53-regulated genes when transcription was inhibited (Figure 4b).
Transcription inhibition of gemcitabine-treated cells blocked
the accumulation of both pro-growth arrest proteins (p21 and
14-3-3s) and pro-apoptotic proteins (Bax and PUMA). After
Cr(VI) exposure, there was little to no reduction in the protein
level of Bax despite the continued presence of actinomycin D,
a response conserved in a range of cell lines, suggesting
that in contrast to gemcitabine, pre-existing Bax could be
stabilized following Cr(VI) exposure, although the exact
mechanism controlling this is currently unknown.
A key characteristic of transcription-independent apoptosis
involves the shuttling of p53 into the cytoplasm. We
investigated the distribution of p53 within our cell lines
following exposure to each agent. In contrast to gemcitabine
(where the majority of p53 was nuclear), Cr(VI) exposure
induced significant accumulation of p53 in the cytoplasm
(Figure 4c). This supports the observation shown in Figure 4a
that following gemcitabine exposure, p53 mediates its cellular
effect at the transcription level, whereas Cr(VI) induces
p53-dependent apoptosis in a transcription-independent
manner. gIR treatment promoted significant nuclear accumu-
lation of p53 consistent with a potent p21-dependent cell cycle
arrest phenotype.
Gemcitabine-induced apoptosis is PUMA-dependent,
whereas Cr(VI)-induced apoptosis is Bax-dependent.
We questioned if the different modes of induction of these
pro-apoptotic BH3 proteins reflected actual differences in
apoptotic outcome. [PUMA / ] or [Bax / ] HCT116 cells
were treated and MTS cell viability assays were carried out
(Figure 5a). The [PUMA / ] HCT116 cells (compared with
[Bax / ] HCT116 cells), had a significantly higher EC50
value (and thus are considerably more resistant) to gemci-
tabine treatment 72 h post drug exposure. In contrast, Cr(VI)-
induced apoptosis was not affected by the PUMA status
within the cell, but was significantly attenuated in the
absence of Bax. Similarly, shRNA knockdown of either
PUMA or Bax induced a similar differential response to each
agent (Figure 5a). The restoration of PUMA or Bax
expression in either knockout cell lines rescued each
phenotype and generated, 72 h post treatment, EC50 values
similar to wild-type cells (Figure 5b). These findings support
the notion that although the loss of p21 or 14-3-3s
significantly enhances cellular susceptibility to stress, distinct
p53-effector pro-apoptotic proteins are critical to instigate
these responses.
In vivo tumour regression after gemcitabine treatment is
PUMA-dependent. Our in vitro studies indicate that when
cell lines are exposed to gemcitabine they induce p53-
dependent apoptosis contingent upon the transcriptional
expression of PUMA. In contrast, Cr(VI) mediates transcrip-
tion-independent cell death and requires only the presence
PUMA and Bax: implications for cancer treatment
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of the p53 and Bax protein. We questioned if this could
be demonstrated in vivo and if these DNA-damaging
agents could trigger regression in established tumours.
[p53þ /þ ] HCT116 tumours were subcutaneously established
in the flanks of NOD/SCID mice and injected intratumourally
with gemcitabine (30 mg/kg in 50 ml based on average tumour
weight) or Cr(VI) (10 mg/kg in 50 ml based on average tumour
weight). Each chemical significantly reduced [p53þ /þ ]
tumour volume 21 days post injection but had no effect on
[p53 / ] HCT116 tumours (Figure 6a), supporting our
in vitro data. With each treatment regime, we noted no
associated toxicity or adverse effects. As expected, each
control group (50ml PBS) showed significant, rapid tumour
growth over the same time period.
To confirm the role(s) of PUMA and Bax following exposure
to each DNA-damaging agent, we repeated our in vivo studies
using the matched [Bax / ] and [PUMA / ] HCT116 cell
lines. We note that [PUMA / ] tumours underwent signifi-
cant regression after Cr(VI) treatment consistent with the wild-
type HCT116 tumours (Figure 6b); however, unlike wild-type
tumours, the [PUMA / ] tumours were resistant to gemcitabine.
The opposite results were obtained when [Bax / ] HCT116
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Figure 3 Differential expression of p21 and 14-3-3s affects sensitivity to chemotherapeutics. (a) Indicated cell lines were exposed to gemcitabine (10 mM), Cr(VI) (30 mM)
or g-IR (10 Gy) for 48 h. Immunoblotting was carried out for p21, 14-3-3s and b-actin. (b) Cells were treated as indicated and qRT-PCR was carried out 24 h post damage for
p21, 14-3-3s and GAPDH. Each assay was conducted in quadruplicate and each set of experiments was repeated three times. (c) The viability of cell lines with p21 or 14-3-3s
knocked out or knocked down was measured after 72 h exposure to the indicated DNA-damaging agents. Results are mean±S.D.; ***Po0.0001. Each assay was conducted
in triplicate, N¼ 3
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tumours were treated, where gemcitabine triggered the
significant reduction of these tumours over the 21 day period
in contrast to Cr(VI), which had no significant effect.
To further confirm our in vitro results, we collected the
tumours 21 days post treatment from each wild-type HCT116
group and measured the protein levels of p53, p21, 14-3-3s,
Bax and PUMA (Figure 6c). In contrast to the untreated
control tumours, both the Cr(VI)- and the gemcitabine-treated
tumours showed significant p53, Bax and PUMA protein
accumulation consistent with our previously described in vitro
studies. As predicted from our in vitro studies, there was the
loss of both the p21 and 14-3-3s proteins following either
DNA-damaging regime. Collectively, these studies show that
gemcitabine-mediated tumour regression is PUMA-dependent
but Bax-independent, whereas Cr(VI)-mediated tumour
regression is Bax-dependent but PUMA-independent, and
that both modalities ablate p21 and 14-3-3s expression/
protein accumulation.
Colon and pancreatic cancer clinical samples show
elevated p21 and Bax expression, but attenuated PUMA
expression. Gemcitabine has been widely used to treat
colon and/or pancreatic cancers, however, this treatment
regiment has met with limited success in clinical trials. Colon
and pancreatic cancers have been shown to contain a high
percentage of p53 mutations34,35 and to determine whether
the relatively low efficacy of this drug could be linked to the
status of p53, PUMA, Bax and p21, clinical samples of colon
or pancreatic cancer were subjected to hematoxylin/eosin
staining and compared with matched normal tissues taken
from each patient. We conducted immunofluorescence
staining for annexinA2 (ANXA2) (as a predominantly cell
surface protein), allowing us to identify the presence,
abundance and subcellular localization of p53 within our
clinical sections. All of our matched clinical samples (tumour
and normal tissue) were obtained during conventional
surgical intervention and, importantly, none of our cancer
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Figure 4 Gemcitabine induces cell death in a transcription-dependent manner. (a) Cell lines indicated were mock/pretreated with actinomycin D (1mg/ml) for 6 h. At 72 h
MTS assays were conducted for the indicated DNA-damaging agents in the presence of actinomycin D. N¼ 3. Results are mean±S.D.; ***Po0.0001. (b) Indicated cell lines
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patients had undergone any other form of disease management
(chemo- or radio-therapy) prior to the surgical removal of the
tumour mass. Noticeably (Figure 7a), we observed signifi-
cantly higher levels of p53 in our colon tumour samples and
little to no p53 in the matched normal colon tissue raising the
hypothesis that targeting this highly stabilised p53 within
these tumours could promote significant tumour regression.
(Due to the nature of pancreatic Whipple surgery, we were
unable to conduct this analysis for our pancreatic samples).
As predicted, based on the high p53 protein expression, we
detected considerably higher p21, 14-3-3s and Bax expression
in the colon tumour tissue compared with the matched normal
colon tissue samples (Figure 7b). This gene expression
profile was also noted for our pancreatic tumour samples.
Despite the disparity in total p53 protein levels, both the colon
and pancreatic tumour samples show similar levels of PUMA
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expression compared with matched normal tissues.
To determine whether the gene expression within these
matched samples correlated with protein levels, we
conducted immunoblot analysis for HIF-1a (a marker of
tumour hypoxia), total and ser15 phosphorylated p53,
PUMA, Bax p21 and 14-3-3s (Figure 7c). We observed little
to no total or phosphorylated p53 in any of our normal colon
tissues samples or in our extracted normal pancreatic
samples. In contrast, all of the colon and pancreatic tumour
samples showed significantly higher levels of total p53 and
phosphorylated ser15 p53, with an average of fivefold higher
levels of total p53 protein within colon cancer lysates and
threefold higher in pancreatic cancer lysates (compared with
matched normal tissue) (Figure 7d). The tumour samples
also possessed higher levels of HIF-1a typically seen in solid
cancerous tissues. Consistent with the gene expression
data, the tumour samples generally displayed higher levels of
p21, 14-3-3s and Bax compared with the matched normal
tissues. In contrast, despite the significant quantity of p53 in
each tumour, the levels of PUMA protein remained very low.
We questioned if the high expression of p21, 14-3-3s and
Bax combined with the low expression of PUMA seen in these
tumour samples was due to differences in p53 binding to the
promoters of these genes. The p21, PUMA and Bax biotin-
tagged promoter sequences were generated (described in our
Materials and Methods) and incubated with our lysed matched
clinical samples, allowing the p53 protein to bind to these
sequences. The bound p53 was then extracted and analyzed
by immunoblotting, (Figure 7e). Following streptavidin pull-
down, non-captured lysates (containing any unbound proteins
p53
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(including any p53 that did not bind) were also kept and
analyzed by immunoblotting. Due to the extremely low levels
of total p53 protein within each normal tissue sample, there
was a low amount of p53 (bound/unbound) on each of the
three tested promoters. When the colon cancer tissues were
similarly analyzed, we noted abundant p53 binding to the p21
and Bax promoters. In contrast, despite the significant
abundance of p53 protein, there was little to no p53 binding
to the PUMA promoter. While the level of p53 protein differed
significantly between normal and cancerous tissue (see
Figure 7d), the percentage of bound p53 (from the total p53
protein pool) was similar, B60–70% for the p21 and Bax
promoter sequences. Strikingly, despite high levels of the p53
protein in our colon cancer lysates,o10% of the total protein
would bind to this promoter region (Figure 7e). Therefore,
expression levels of these p53 target genes appear to
correlate with the capacity of p53 to bind to these promoters.
Discussion
We show that gemcitabine and chromium exposure each
instigates p53-dependent apoptosis in contrast to g-IR-
induced DNA damage that mediates a potent p53-regulated
cell cycle arrest response. Cells exposed to g-IR also show
elevated levels of expression of the pro-apoptotic genes (Bax,
PUMA, Bid), suggesting that expression of these is a default
response to DNA damage. A major difference is found in the
expression of the pro-growth arrest genes p21 and 14-3-3s,
where g-IR enhances their expression (triggering arrest),
whereas agents that induce cell death suppress their
expression. This downregulation is a prerequisite for the
induction of apoptosis as the loss/reduction of either p21 or
14-3-3s significantly increases cell line sensitivity to each
apoptotic agent, and the combined loss of p21 and 14-3-3s
synergistically enhances this sensitivity.
Although gemcitabine and Cr(VI) each induce p53-dependent
apoptosis, their modes of action are very different.
Gemcitabine mediates a transcription-dependent apoptotic
response compared with Cr(VI) that instigates a transcription-
independent apoptosis response. Although the loss of p21 or
14-3-3s globally promotes/sensitizes cells to apoptosis, there
is an absolute requirement to upregulate pro-apoptotic
proteins for gemcitabine to trigger cell death. Subsequent
gene knockout, knockdown and restoration studies revealed
that the protein in question is PUMA. In contrast, chromium
exposure results in the stabilization of pre-existing Bax protein
that is responsible for triggering the subsequent apoptosis;
PUMA is not involved in this event. It thus appears that the
upregulation of Bax (and PUMA) following chromium treat-
ment is superfluous, although Bax must be initially present
prior to cellular exposure to Cr(VI) to instigate the potent
apoptotic response. This is congruent with the concept that
global upregulation of pro-apoptotic gene expression is a
default response to any type of DNA damage that needs to be
suppressed when an apoptotic outcome is undesirable.
Subsequent refinement in terms of specific pathway selection,
candidate protein identification and usage would depend on
the nature of the damage/stress.
Our in vivo studies also showed that gemcitabine induced
PUMA-dependent tumour regression and Cr(VI) mediated
Bax-dependent tumour destruction. An important caveat
relates to Cr(VI) exposure. Clearly, Cr(VI) is a potent chemical
and, like all currently utilized chemotherapeutic agents, when
injected systemically could induce significant side effects.
These were not observed following the direct intratumoural
injection of this chemical, and it should also be noted that the
dose used was tolerated systemically over a prolonged
period of time.22,36 It is also important to note that the
chemotherapeutics routinely being administered have highly
toxic side effects (e.g., the cardiotoxicity following doxorubicin
regimes37,38). What is apparent from these studies is that
various agents can specifically activate different ‘arms’of the
p53 apoptotic response and that targeting both PUMA and Bax
could be a highly viable approach (summarized in Figure 8).
The prognosis for patients with advanced pancreatic
adenocarcinoma is extremely poor. Despite significant
research, combination regimes with gemcitabine have yielded
only a minor improvement over conventional therapies.39,40
What is clear is that in our tumour samples there was
significantly higher total p53 protein. We were unable to
determine whether the p53 within our tumour samples
harboured any/multiple p53 mutations; however, this protein
was able to bind to the p21 and Bax promoters, while these
tumours also displayed elevated expression of these genes.
Although these promoter regions could be bound (and
transcribed), there clearly was an effect upon PUMA promoter
recruitment where despite the increased p53 protein, there
was little to no protein binding.
At present, there is an urgent need for both new treatment
options and an improved understanding of how gemcitabine
mediates its anti-cancer effects. Our demonstration that
gemcitabine mediates its potent anti-tumour effect via p53
and PUMA in a transcription-dependent manner explains, at
least in part, why clinical results with this agent have been
significantly lower than what one would have predicted. As the
vast majority of human cancers harbour p53 mutations that
reduce DNA-binding, a drug whose mechanism of action
requires efficient upregulation of PUMA would only be useful
in tumours that harbour transcriptionally active p53. This
draws on a recent phase II and III clinical trial finding that
gemcitabine in combination with axitinib, erlotinib or cisplatin
did not dramatically improve survival for patients with
advanced pancreatic cancer.18,41,42 Our clinical results show
that pancreatic and colon cancer samples generally contain
relatively high levels of p21, 14-3-3s and Bax (compared with
normal tissues), high levels of total p53 protein and low levels
of PUMA protein. This raises the hypothesis that the low level
of PUMA could be due to alternative mechanisms (other than
simply being a downstream target of p53). PUMA protein
stability could be negatively affected in cancer cells compared
with normal cells or other components of the cellular
transcription machinery could be ablating PUMA transcription
in transformed cells. This is particularly interesting when p21
and 14-3-3s are considered because the loss of these
proteins would sensitize cancer cells to a range of different
therapeutic approaches, yet p53 (either wild-type or mutant
p53) is able to drive the transcription of these genes in cancer
patients. This suggests a dual approach for the treatment of
such cancers: stabilization of Bax coupled with suppression or
inhibition of p21 and/or 14-3-3s.
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Materials and Methods
Cell lines and culture. [p53þ /þ ], [p53 / ], [p21 / ], [14-3-3s / ],
[PUMA / ], [Bax / ], [p21 /14-3-3s / ], [p21 /PUMA / ] and
[p21 /Bax / ] HCT116 human colon carcinoma cells (a gift from B.
Vogelstein, Johns Hopkins University), U2OS and SOAS2 human osteosarcoma
(ATCC) were maintained in McCoy’s 5A medium, 10% FBS and antibiotics.
Panc-1 (ATCC) and MDA-Panc-3 (a gift from N. Lemoine, originally generated by
M Frazier, University of Texas) human pancreatic carcinoma cell lines were
maintained in DMEM supplemented with 10% FBS and antibiotics.
Reagents and antibodies. Total cell lysate was prepared from cells
(50 mM Tris-HCl pH 7.4, 1% NP-40, 0.5% Na-deoxychlorate, 150 mM NaCl, 1 mM
EDTA, 2 mM NaF, 2 mM NaVO4 and 1 PIC (Sigma, St. Louis, MO, USA)) and
fractionated as described in Grayson et al.43 Actinomycin D (ActD) was used at
1mg/ml (Sigma, US). Antibodies against p53 (DO1), p21 (C-19), 14-3-3s,
caspase-9, tubulin and b-actin (Santa Cruz, Dallas, TX, USA), PUMA, caspase-2,
caspase-3, Bax and Bcl-2 (Cell Signalling, Danvers, MA, USA). Visualization of
signal was achieved using an Odyssey infrared Imaging System (Licor Bioscience,
Lincoln, NE, USA). A detailed description of each antibody and the conditions
used is described in our Supplementary Data.
Dose response analysis. Cells were seeded in 96-well plates at 1 104
cells per well and 24 h later treated with various DNA-damaging agents (gemcitabine
hydrochloride (Eli Lilly #VL7502) and K2CrO7 (Cr(VI)) (both Sigma) at the
concentrations described. Cell survival was determined by CellTiter 96 Aqueous
non-radioactive proliferation assay (MTS assay; Promega, Madison, WI, USA).
Quantitative real time PCR. Total RNA was extracted by using Trizol
(Invitrogen, Grand Island, NY, USA). Real time PCR was performed on a
Stratagene MX3000P PCR machine using the Stratagene Sybr green master
mix (Stratagene, La Jolla, CA, USA). The primer sequences for measuring p21,
14-3-3s, Bcl-2, Bcl-XL, BID, Bax, PUMA and GAPDH (Invitrogen) are described in
detail in our Supplementary Data. Data analysis was carried out using the 2DDCT
method described by Livak et al.44
Annexin-V analysis. Cells were treated with 10mM gemcitabine, 30mM
Cr(VI) or 10 Gy g-IR and incubated for an additional 48 h. Cells were staining for
Annexin-V (BD Pharmigen, Mississauga, ON, USA) following the manufacturer’s
instructions.
p53-promoter binding analysis. The promoter sequences (containing the
p53 responsive element) for p21 BAX and PUMA were obtained from Invitrogen
with their 50 biotin-tagged. Complementary, non-tagged sequences were obtained
for each gene generating dsDNA sequences. dsDNA sequences were bound to
streptavidin-conjugated magnetic beads generating dsDNA probes. 200mg of
clinical lysate were pre-mixed with 10 mg of poly(dI-dC) (Sigma) and mixed at 4 1C
for 1 h. Samples were added to each dsDNA-bead probe and incubated at 4 1C for
1 h and mixed end-over-end. Both captured and non-captured lysates were
isolated and analysed by SDS-PAGE electrophoresis (addressing p53-promoter
recruitment).
Animal studies. Eight-week-old male NOD/SCID mice (Charles River,
Wilmington, MA, USA) were divided into treatment groups (N¼ 7). Mice were
injected subcutaneously with 2 106 cells in PBS. Control groups received
intratumoural injections of PBS, whereas the treatment groups received 2 doses of
20 mg per kg gemcitabine or 10 mg per kg K2CrO7 Cr(VI) on day 1 and day 4
based on tumour weight. Tumour volume was measured thrice weekly (digital
callipers) and calculated using the formula: (lengthwidthwidth)/3.142, where
length is the larger diameter of the tumour (mm). Animals were culled by CO2
asphyxiation and tumours excised for analysis. The experimental design was
vetted by the Dalhousie University Ethical Committee and met all standards
required by the Canadian authority for animal welfare.
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Figure 8 Proposed ‘arms’ of the p53 apoptotic response. Under apoptotic conditions (e.g. gemcitabine or CrVI)), p53 is activated and accumulates. Following gemcitabine
exposure, p53 accumulation is predominately nuclear inducing the transcription of PUMA (in addition to Bax and other p53-regulated genes). Following the accumulation of
PUMA protein, there is a significant induction of PUMA-dependent/transcription-dependent apoptosis. In contrast, Cr(VI) exposure induces p53 accumulation (and subsequent
transcription of Bax and PUMA); however, this is not a crucial requirement to induce apoptosis as there is a significant accumulation of p53 (and Bax) protein within the
cytoplasm of Cr(VI)-exposed cells. As a result, Cr(VI) induces a potent Bax-dependent/transcription-independent apoptotic response characterized by p53 and BAx protein
accumulation in the cytoplasm of exposed cells. Regardless of the crucial effector protein, both modalities ablate p21 and 14-3-3s expression, priming the cell to induce
apoptosis
Figure 7 Primary colon and pancreatic tumours display elevated p53 and attenuated PUMA protein expression. (a) H&E staining was conducted following surgical
removal of colon tumour and matched normal tissue. Scale bars (low magnification) indicate 100mm and 40mm (high magnification). Immunofluorescence staining was
carried out from snap-frozen tumour tissue immediately after surgical removal. Sections were stained for ANXA2 (cell surface marker) and p53. (b) Colon (N¼ 8) and
pancreatic (N¼ 6) tumour samples (including matched normal tissue) were surgically removed. qRT-PCR was conducted for p21, 14-3-3s, Bax, PUMA and GAPDH in
quadruplicate (c) Colon tumour, pancreatic tumour and matched normal tissue were surgically removed and homogenized, and proteins were extracted. Samples (100mg)
were analyzed by immunoblotting for HIF-1a, Phospho-Ser15 p53, total p53, b-actin, p21 14-3-3s, PUMA and Bax. (d) The average amount of total p53 protein was quantified
and the mean average±S.D. (N¼ 8 and 6, respectively) was plotted for both of our normal and cancer samples. (e) Fifty microgram of the total protein extract from c was
incubated with our generated, specific biotinylated promoter sequences for the p21, Bax or PUMA genes addressing p53 recruitment/binding. Following capture, protein/DNA
complexes were separated using streptavidin beads (Invitrogen). Proteins were removed, denatured and analysed by immunobotting for total p53. Non-captured/promoter
bound p53 protein was similarly analyzed. (f) Each sample (bound/unbound p53) from each sample (normal or colon cancer) was quantified and the percentage of bound p53
protein was calculated. The mean average percentage±S.D. was plotted and P-values comparing the percentage bound between normal/cancer samples was calculated
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Clinical sample collection. Core tumour samples of colon carcinoma were
obtained from patients with colon cancer at the time of their surgery. At the time, a
section of matched normal colon tissue was extracted adjacent to the tumour site.
Pancreatic tumour tissue (and matched normal tissue) was obtained during
surgery (Whipple protocol). Patient consent and ethical approval was obtained for
each procedure from the Research Ethics Board, (VG Hospital, Halifax, Nova
Scotia, Canada).
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